Skip to main content
. Author manuscript; available in PMC: 2016 Nov 6.
Published in final edited form as: Circ Res. 2015 Sep 17;117(11):956–966. doi: 10.1161/CIRCRESAHA.115.306783

Figure 6. Inhibition of CRLs impairs CryABR120G ubiquitination and degradation in cardiomyocytes.

Figure 6

(A) CSN8 knockdown impairs CryABR120G ubiquitination. NVRMs were treated as described in Figure 5. Seventy-two hours after siRNA transfection, MG132 (5 µmol/L) treatment was initiated and lasted for 6 hours before the cells were harvested. Representative images of western blot analyses (IB) of the indicated proteins in immunoprecipitated (IP) HA-CryABR120G are shown. (B, C) MLN4024 stabilizes CryABR120G in cultured NRVMs. MLN4924 (1µmol/L) or vehicle control (DMSO) treatment was initiated at 48 hours after Ad-HA-CryABR120G infection in cultured NRVMs. Cycloheximide (CHX, 50µmol/L) was added to the culture media at 30min after initiating MLN4924 treatment. Cells were harvested at the indicated time points for extraction of total proteins. Representative images (B) and pooled densitometry data (C) of western blot analyses of HA-CryABR120G are shown. *p<0.05 vs. the DMSO group, n=3 repeats; t-test.